212842-64-3

Basic information

• Product Name: Cowaxanthone B
• Synonyms: Cowaxanthone B;1,3-Dihydroxy-6,7-dimethoxy-2,8-bis(3-methyl-2-butenyl)-9H-xanthen-9-one
• CAS NO: 212842-64-3
• Molecular Formula: C25H28O6
• Molecular Weight: 424.48622
• Mol File: 212842-64-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 91-92℃ (methanol )
• Appearance: /
• CAS DataBase Reference: Cowaxanthone B(CAS DataBase Reference)
• NIST Chemistry Reference: Cowaxanthone B(212842-64-3)
• EPA Substance Registry System: Cowaxanthone B(212842-64-3)

Safety Data

• Hazardous Substances Data: 212842-64-3(Hazardous Substances Data)

Usage

General Description

Cowaxanthone B is a chemical compound derived from the roots of the plant Polyalthia suberosa. It belongs to the xanthone class of compounds and has been studied for its potential biological and medicinal properties. Research has shown that Cowaxanthone B exhibits anti-inflammatory, antioxidant, and cytotoxic effects, making it a potential candidate for the development of new pharmaceuticals. Its ability to inhibit the growth of cancer cells and its potential as a natural anti-inflammatory agent make it a promising area of study for the treatment of various diseases. Additionally, Cowaxanthone B has been found to have antimicrobial properties, further expanding its potential applications in medicine and healthcare.

Upstream product

• 6147-11-1 α-mangostin 
• 74-88-4 methyl iodide 

Relevant articles and documents

Modified tetra-oxygenated xanthones analogues as anti-MRSA and P. aeruginosa agent and their synergism with vancomycin

Five isolated xanthones from the C. cochinchinense and G. mangostana were evaluated and tested for antibacterial activities. Isolated 4 and 5 exhibited potent anti-MRSA and P. aeruginosa activity, but showed poor pharmacokinetic properties via ADMET prediction. It led us to improve pharmacokinetic properties of 4 and 5 by partially modifying them in acidic condition yielding fourteen analogues. It was found that analogues 4b, 4d and 5b possessed proper pharmacokinetic properties, while only 4b exhibited the best anti-MRSA and P. aeruginosa activity. The SEM results indicated that 4b may interact with or damage the cell wall of MRSA and P. aeruginosa. Moreover, a combination of 4b and vancomycin exhibits synergistic effect against both MRSA and P. aeruginosa at MIC value of 4.98 (MIC = 18.75 μg/mL for 4b) and 9.52 μg/mL (MIC = 75 μg/mL for 4b), respectively.

Potent activity against multidrug-resistant Mycobacterium tuberculosis of α-mangostin analogs

A new series of mangostin analogs of natural α-mangostin from mangosteen was prepared and their antimycobacterial activity was evaluated in vitro against Mycobacterium tuberculosis H37Ra. The results showed that the monoalkyl tetrahydro α-mangostin analogs displayed increased antimycobacterial activity as compared with the lead natural xanthone, α-mangostin. Among the tested compounds, 6-methoxytetrahydro α-mangostin (16) exhibited the most potent antimycobacterial activity with minimum inhibitory concentration (MIC) of 0.78 μg/mL. The activity of the monoalkylated and monoacylated tetrahydro α-mangostins decreases as the length of carbon chain increases. The methyl ether analog was also active against the multidrug- resistant (MDR) strains with pronounced MICs of 0.78-1.56 μg/mL.